We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
MRK Stock Up Nearly 14% So Far This Week: What's Driving It?
Read MoreHide Full Article
Key Takeaways
Merck stock jumps almost 14% as investor optimism grew after Pfizer's drug pricing deal.
The deal boosts sector sentiment by reducing drug costs and driving investment in the U.S. pharma sector.
Investor optimism lifted Merck and other big drugmakers like AstraZeneca, Eli Lilly and others.
Shares of Merck (MRK - Free Report) have rallied almost 14% so far this week as investors’ optimism grew concerning the broader pharmaceutical sector in the United States after Pfizer (PFE - Free Report) announced a landmark deal with the Trump administration. The deal aims to reduce prescription drug costs while boosting investment in U.S.-based innovation and manufacturing.
With the latest deal, PFE is looking to reduce prices of some of its drugs to align their cost with those in comparable developed countries, supporting President Trump’s Most Favored Nation (MFN) pricing proposal. Pfizer will also offer significant discounts through the new direct purchasing platform, TrumpRx.gov, while committing an additional $70 billion over the coming years to strengthen its U.S. research and production operations. In return, Pfizer will be granted a three-year exemption from tariffs on pharmaceutical imports if it increases U.S. manufacturing investment.
Stocks of most other large drugmakers like Merck gained too, as the Pfizer deal seems to have alleviated the two biggest concerns surrounding the drug and biotech industry this year – tariff and MFN pricing.
If Merck can sign a similar pricing deal with the Trump administration, it will provide more impetus to the stock.
The company tasted a major regulatory success last month, when the FDA approved the subcutaneous (SC) formulation of its blockbuster PD-L1 inhibitor, Keytruda. This SC version will be marketed as Keytruda Qlex and is approved across most solid tumor indications for which the drug’s intravenous (IV) version is already approved.
With Keytruda IV set to lose exclusivity in 2028, the newly approved SC version carries its own patents that extend protection well beyond that timeline. By helping physicians and patients toward the SC formulation, the company can maintain a significant portion of Keytruda’s revenues even after the original IV patents expire.
Benefits for Other Drug Makers
Pfizer’s latest drug pricing deal removes a significant overhang for the broader pharma industry and brings renewed interest from investors, triggering a price rally in the given sector. Besides Merck, stocks of other large drugmakers like AstraZeneca (AZN - Free Report) , Eli Lilly (LLY - Free Report) and AbbVie, among others, gained too. Both Lilly and AstraZeneca have already gained around 13% while AbbVie has risen around 7% so far this week. Investors’ confidence is growing on the belief that these companies could follow PFE’s footsteps and sign similar deals with the Trump administration, which could hugely benefit the broader pharma sector.
In response to Trump’s tariff threats, many large drugmakers have already committed billions to ramp up U.S. investments to boost domestic production.
Lilly has announced plans to invest $27 billion to develop four new manufacturing sites in the United States by 2025.
AstraZeneca announced plans to invest $50 billion in U.S. manufacturing and research and development (R&D) by 2030. AZN’s plan includes a new multi-billion-dollar manufacturing facility to be set up in Virginia.
Several other companies like J&J, GSK, Novartis and Roche have also committed billions in U.S. manufacturing and R&D investments.
MRK's Price Performance, Valuation and Estimates
Year to date, shares of Merck have declined 10% against the industry’s rise of 8.3%. The stock has also underperformed the sector and the S&P 500 during the same time frame, as seen in the chart below.
Image Source: Zacks Investment Research
From a valuation standpoint, Merck appears attractive relative to the industry. Going by the price/earnings ratio, the company’s shares currently trade at 9.49 forward earnings, lower than 15.93 for the industry and its 5-year mean of 12.67.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for 2025 earnings per share has remained stable at $8.93 per share, while the same for 2026 has decreased from $9.61 to $9.59 over the past 60 days.
Image: Bigstock
MRK Stock Up Nearly 14% So Far This Week: What's Driving It?
Key Takeaways
Shares of Merck (MRK - Free Report) have rallied almost 14% so far this week as investors’ optimism grew concerning the broader pharmaceutical sector in the United States after Pfizer (PFE - Free Report) announced a landmark deal with the Trump administration. The deal aims to reduce prescription drug costs while boosting investment in U.S.-based innovation and manufacturing.
With the latest deal, PFE is looking to reduce prices of some of its drugs to align their cost with those in comparable developed countries, supporting President Trump’s Most Favored Nation (MFN) pricing proposal. Pfizer will also offer significant discounts through the new direct purchasing platform, TrumpRx.gov, while committing an additional $70 billion over the coming years to strengthen its U.S. research and production operations. In return, Pfizer will be granted a three-year exemption from tariffs on pharmaceutical imports if it increases U.S. manufacturing investment.
Stocks of most other large drugmakers like Merck gained too, as the Pfizer deal seems to have alleviated the two biggest concerns surrounding the drug and biotech industry this year – tariff and MFN pricing.
If Merck can sign a similar pricing deal with the Trump administration, it will provide more impetus to the stock.
The company tasted a major regulatory success last month, when the FDA approved the subcutaneous (SC) formulation of its blockbuster PD-L1 inhibitor, Keytruda. This SC version will be marketed as Keytruda Qlex and is approved across most solid tumor indications for which the drug’s intravenous (IV) version is already approved.
With Keytruda IV set to lose exclusivity in 2028, the newly approved SC version carries its own patents that extend protection well beyond that timeline. By helping physicians and patients toward the SC formulation, the company can maintain a significant portion of Keytruda’s revenues even after the original IV patents expire.
Benefits for Other Drug Makers
Pfizer’s latest drug pricing deal removes a significant overhang for the broader pharma industry and brings renewed interest from investors, triggering a price rally in the given sector. Besides Merck, stocks of other large drugmakers like AstraZeneca (AZN - Free Report) , Eli Lilly (LLY - Free Report) and AbbVie, among others, gained too. Both Lilly and AstraZeneca have already gained around 13% while AbbVie has risen around 7% so far this week. Investors’ confidence is growing on the belief that these companies could follow PFE’s footsteps and sign similar deals with the Trump administration, which could hugely benefit the broader pharma sector.
In response to Trump’s tariff threats, many large drugmakers have already committed billions to ramp up U.S. investments to boost domestic production.
Lilly has announced plans to invest $27 billion to develop four new manufacturing sites in the United States by 2025.
AstraZeneca announced plans to invest $50 billion in U.S. manufacturing and research and development (R&D) by 2030. AZN’s plan includes a new multi-billion-dollar manufacturing facility to be set up in Virginia.
Several other companies like J&J, GSK, Novartis and Roche have also committed billions in U.S. manufacturing and R&D investments.
MRK's Price Performance, Valuation and Estimates
Year to date, shares of Merck have declined 10% against the industry’s rise of 8.3%. The stock has also underperformed the sector and the S&P 500 during the same time frame, as seen in the chart below.
Image Source: Zacks Investment Research
From a valuation standpoint, Merck appears attractive relative to the industry. Going by the price/earnings ratio, the company’s shares currently trade at 9.49 forward earnings, lower than 15.93 for the industry and its 5-year mean of 12.67.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for 2025 earnings per share has remained stable at $8.93 per share, while the same for 2026 has decreased from $9.61 to $9.59 over the past 60 days.
Image Source: Zacks Investment Research
MRK’s Zacks Rank
Merck currently has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.